Expression of estrogen receptor variants

Recent data suggest that the expresson of estrogen receptor (ER) variants may be common in clinical breast cancer. The significance of their expression is complicated by the fact that they are often coexpressed with wild‐type ER in the same tumor. We have focused upon one such ER variant which lacks exon 5 within the hormone binding domain of the receptor. This deletion introduces a stop codon, resulting in a truncated ER of 40 kDa which is unable to bind hormone. We have been exploring the hypothesis that this variant may contribute to clinical antiestrogen resistance. Coexpression of the exon 5 variant along with wild‐type ER in MCF‐7 human breast cancer cells confers resistance to the commonly used antiestrogen, tamoxifen. In addition, we have observed that some metastatic breast lesions overexpress exon 5 ER deletional variant transcripts. We conclude that differences in the relative amounts of several ER variants in the same tumor may interact to determine hormonal responsiveness and metastatic behaviour.

[1]  M. Parker,et al.  Structure and Function of the Estrogen Receptor , 1993, Annals of the New York Academy of Sciences.

[2]  S. Fawell,et al.  Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. , 1993, Molecular endocrinology.

[3]  B. Katzenellenbogen,et al.  Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination. , 1992, The Journal of biological chemistry.

[4]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[5]  A. D. Schryver,et al.  Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .

[6]  C. Osborne,et al.  Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. , 1991, Journal of the National Cancer Institute.

[7]  W. McGuire,et al.  Variant human breast tumor estrogen receptor with constitutive transcriptional activity. , 1991, Cancer research.

[8]  R. Daly,et al.  Cellular and molecular events in loss of estrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells. , 1990, Cancer research.

[9]  P. Chambon,et al.  Functional domains of the human estrogen receptor , 1987, Cell.